Management of Post-heart Transplant Atrial Fibrillation

Abstract

AF is the most common atrial arrhythmia encountered after orthotopic heart transplantation, with distinct pathophysiology and clinical implications. While early postoperative AF is typically transient, late-onset AF is increasingly recognised as a marker of graft dysfunction, rejection or vasculopathy. Risk factors include advanced recipient age, prolonged ischaemic time and immunosuppressive therapy. The denervated status of the transplanted heart alters typical electrophysiology, complicating diagnosis and management. Management requires individualised strategies balancing rate versus rhythm control, careful drug interaction monitoring and thromboembolic risk assessment. Emerging evidence supports catheter ablation in select cases, although data remain limited. Immunosuppressants, particularly calcineurin inhibitors and azathioprine, may increase AF susceptibility. Given the lack of transplant-specific AF guidelines, a multidisciplinary approach is essential. Improved understanding of AF in orthotopic heart transplantation is critical to optimising graft longevity and patient survival. Future studies are needed to guide evidence-based management and surveillance.

AF represents the most common sustained atrial arrhythmia encountered in clinical practice, and carries significant morbidity and mortality in the general population. In the context of orthotopic heart transplantation (OHT), AF presents with distinct pathophysiological mechanisms, diagnostic challenges and clinical implications. While the denervated status of the transplanted heart may alter typical arrhythmic triggers and conduction patterns, atrial arrhythmias – including AF – remain an important post-transplant complication. These arrhythmias may reflect underlying graft pathology, such as rejection, vasculopathy or atrial remodelling secondary to surgical technique. Given its association with adverse outcomes – including graft dysfunction, hospitalisation and mortality – early recognition and targeted management of AF in heart transplant recipients are essential. Despite its clinical importance, standardised guidelines for surveillance, risk stratification and management remain limited, underscoring the need for a deeper understanding of AF in this unique patient population.

Epidemiology and Clinical Significance

AF is a recognised complication following OHT, with reported incidences varying widely depending on the timing post-transplant and detection methods used. Early postoperative AF occurs in approximately 10–20% of patients and is often transient, while late-onset AF develops in a smaller subset, but carries significant prognostic implications.1,2 Long-term studies indicate that the cumulative incidence of AF can reach up to ≥20%, with some reports documenting a 5-year incidence of 10–15%.3,4 Compared with non-transplant cardiac surgery populations, heart transplant recipients demonstrate a distinct arrhythmic profile characterised by a relatively lower incidence of postoperative AF, but a higher propensity for atrial flutter and other supraventricular arrhythmias.2,5

AF in the transplanted heart is clinically significant due to its association with adverse outcomes, including increased risk of allograft rejection, graft dysfunction, hospitalisations and mortality.6,7 Notably, episodes of AF have been correlated with concurrent acute cellular or antibody-mediated rejection, suggesting that arrhythmia may serve as a clinical marker for underlying graft injury.8 Furthermore, AF contributes to haemodynamic compromise in the denervated heart, which relies heavily on optimal atrial function to maintain cardiac output, thereby exacerbating heart failure symptoms and increasing rehospitalisation risk.1,6

Risk factors implicated in post-transplant AF include older recipient age, longer ischaemic times, graft vasculopathy and episodes of rejection or infection.3,8 Immunosuppressive therapies, particularly those affecting electrolyte balance and autonomic regulation, may further predispose patients to arrhythmogenesis.1,7 The clinical burden of AF is compounded by challenges in diagnosis due to atypical electrocardiographic features in the denervated heart and the necessity for close monitoring to detect paroxysmal episodes.2,9

While atrial flutter and other supraventricular tachycardias are also observed in this population, AF remains the most prevalent atrial arrhythmia with the greatest impact on long-term outcomes.5 Understanding the epidemiology and clinical implications of AF post-transplant is crucial for optimising surveillance strategies, and tailoring management to improve graft and patient survival.

Mechanisms of AF in the Transplanted Heart

AF in the post-heart transplant population arises from a complex interplay of factors unique to the transplanted heart’s anatomy and physiology. One hallmark characteristic influencing arrhythmogenesis is cardiac denervation following transplantation, which alters autonomic regulation and atrial electrophysiology. The loss of parasympathetic and sympathetic innervation disrupts normal atrial refractoriness and conduction, thereby predisposing to re-entrant circuits and ectopic activity.1,2,9 This denervation also modifies the typical ECG presentation of AF, complicating diagnosis and monitoring.2,9

Surgical factors significantly contribute to AF substrate formation. The biatrial or bicaval anastomosis techniques used during transplantation produce atrial scarring and regions of conduction block. In addition to suture line-related remodelling, recipient-to-donor atrio-atrial connections may develop following OHT and have been identified in approximately 21% of recipients presenting with atrial tachyarrhythmias. These connections create zones of electrical continuity between residual native atrial tissue and the donor atrium, providing potential foci for arrhythmogenesis and re-entrant propagation. Clinically, patients with atrio-atrial connections more frequently show arrhythmias originating in the recipient atrium – such as focal atrial tachycardia or AF – with conduction spreading into the donor atrium, whereas patients without such connections more commonly present with donor-atrium arrhythmias, including cavotricuspid isthmus-dependent atrial flutter. Computational modelling further demonstrates that propagation across an atrio-atrial connection requires an isthmus width of at least 2 mm, with conduction characteristics influenced by cycle length and anatomical location.5 These regions therefore contribute to increased susceptibility to AF and other atrial arrhythmias, such as atrial flutter.2,10 Additionally, the allograft’s atrial geometry and fibrosis resulting from ischaemia-reperfusion injury further promote electrophysiological heterogeneity.2,3

Rejection episodes, both cellular and antibody-mediated, induce myocardial inflammation, oedema and fibrosis, which destabilise atrial tissue electrophysiology and may precipitate AF.6,8 Clinical correlations have demonstrated temporal associations between rejection and atrial arrhythmias, suggesting that AF may function as a marker of graft injury.8 Moreover, graft vasculopathy and chronic allograft dysfunction contribute to atrial remodelling and increased arrhythmogenic potential.3,4

Immunosuppressive agents, critical for graft survival, paradoxically influence arrhythmia risk. Calcineurin inhibitors, such as tacrolimus and cyclosporine, have proarrhythmic properties mediated by effects on ion channel function, electrolyte imbalances and autonomic modulation.1,7 These drugs also interact with antiarrhythmic agents, complicating pharmacological management.7 Corticosteroids and other immunosuppressants can contribute indirectly by exacerbating hypertension, diabetes and metabolic derangements that promote atrial remodelling.

Collectively, these transplant-specific factors create a distinctive electrophysiological environment that predisposes heart transplant recipients to AF. Understanding these mechanisms is essential for tailoring diagnostic and therapeutic approaches in this unique patient population.

Diagnostic Workup

A comprehensive diagnostic workup is essential following heart transplantation, and ECG plays a central role in this process. ECGs in heart transplant recipients show distinct characteristics, the most prominent of which is an elevated resting heart rate due to cardiac denervation. As stated earlier, this results from the loss of parasympathetic innervation; although some studies suggest variable degrees of reinnervation over time, this remains a topic of ongoing investigation. Denervation leads to higher baseline resting heart rate, blunted heart rate response to exercise and reduced peak heart rates typically achieved during exercise.11,12

Post-transplant ECGs typically demonstrate normal sinus rhythm. While the P wave axis is often preserved, QRS axis deviation is observed in approximately 23% of patients, with right axis deviation being more common. Right intraventricular conduction delay is also frequent, affecting nearly 50% of patients. Furthermore, evidence of atrial enlargement is common, with 64% of patients meeting ECG criteria. Left atrial enlargement is the most prevalent, presenting in 55% of cases. This atrial enlargement is thought to be related to the surgical technique, particularly the retention of portions of the native atrial tissue.13

AF is the most common arrhythmia after cardiac surgery, but in the context of heart transplantation, it warrants special consideration. Both biatrial and bicaval techniques of transplantation involve isolation of pulmonary vein muscle sleeves from the recipient. However, the biatrial approach has been associated with greater electrical conduction abnormalities due to atrial distortion and is therefore less favoured.

Currently, there are no formal guidelines recommending routine ambulatory cardiac monitoring following transplantation. Nonetheless, in the presence of new or unexplained symptoms, an external ambulatory monitor can be a valuable tool in detecting arrhythmia. Similarly, there is no consensus on the use of implantable cardiac monitors post-transplant, and their use is typically reserved for patients with concerning symptoms, such as unexplained syncope.14

Echocardiography remains a fundamental component of the diagnostic evaluation in heart transplant recipients, especially in cases of newly diagnosed AF. As the first-line imaging modality, it provides critical information on graft anatomy, biventricular function and valvular integrity. While no specific guidelines exist regarding the frequency of echocardiographic surveillance post-transplant, it is generally recommended when there is clinical suspicion of graft dysfunction or a change in the patient’s condition.15

Invasive haemodynamic monitoring using right heart catheterisation is advised by the International Society for Heart and Lung Transplantation in cases where there is suspected acute allograft rejection, signs of poor end-organ perfusion, or concern for restrictive physiology or cardiac allograft vasculopathy.16

Endomyocardial biopsy remains the gold standard for diagnosing acute allograft rejection for now. Per International Society for Heart and Lung Transplantation guidelines, it is typically performed biweekly during the first 3 months post-transplant, monthly for the subsequent 3 months, then every 6–8 weeks through the end of the first year. Beyond the first year, biopsy frequency is usually reduced to an annual basis or performed as clinically indicated, such as in the setting of new onset or signs of graft dysfunction.17

Non-invasive imaging is also used in post-heart transplant recipients. CT is useful in the evaluation of cardiac allograft vasculopathy, allowing detection of luminal irregularities and coronary lesions. In addition, cardiac MRI may assist in identifying myocardial fibrosis through late gadolinium enhancement, potentially aiding in the non-invasive detection of rejection.18

Management Strategies

The development of AF in heart transplant recipients should prompt a comprehensive and systematic evaluation aimed at identifying and addressing any underlying pathophysiological triggers. This is critical, as AF in this population is often a harbinger of significant graft-related complications. Among the primary aetiologies to be considered are acute allograft rejection, transplant-associated heart failure and cardiac allograft vasculopathy.

The previously outlined diagnostic approach – including ECG, echocardiography, haemodynamic assessment and biopsy – should be used to guide management. Integrating these modalities provides a comprehensive picture of graft health and informs therapeutic decision-making. Once an underlying aetiology is identified, targeted interventions should be promptly initiated to optimise graft function and mitigate arrhythmia recurrence.

Management of AF in heart transplant recipients requires careful consideration of both rate and rhythm control strategies. Currently, there is insufficient high-quality evidence to definitively recommend the superiority of either approach in this unique population. Therefore, a patient-centred, individualised strategy remains paramount. Rate control may be appropriate for asymptomatic patients who maintain stable graft systolic function without signs of haemodynamic compromise. However, traditional rate-controlling agents require cautious use in this setting. Notably, digoxin is generally discouraged due to its reduced efficacy in the denervated heart, where parasympathetic innervation is absent, limiting its ability to modulate atrioventricular nodal conduction effectively.11

When rhythm control is pursued, antiarrhythmic therapy must be carefully tailored, with meticulous attention to potential drug–drug interactions, especially given the polypharmacy common in transplant recipients who are maintained on complex immunosuppressive regimens. Class IC antiarrhythmics should be used with caution, and generally avoided until cardiac allograft vasculopathy has been excluded and left ventricular function is confirmed to be preserved. Electrical cardioversion remains a safe and effective option for the acute restoration of sinus rhythm when clinically indicated.

Emerging evidence from case reports and small series suggests that catheter ablation for AF can be performed safely in heart transplant recipients, offering potential for durable rhythm control. In observational cohorts of OHT recipients undergoing ablation for atrial arrhythmias, acute procedural success rates have been high with a low incidence of major complications, and long-term follow-up has demonstrated favourable arrhythmia control and recurrence-free survival, supporting ablation as an effective rhythm control strategy in appropriately selected patients.19 However, robust data from larger, multicentre studies are lacking, and further investigation is necessary to establish the long-term safety, efficacy and outcomes of ablation therapy in this specialised cohort.1,20

Compared with other cardiothoracic surgery populations, atrial flutter is more frequently observed than AF after OHT. Unlike AF, atrial flutter is not consistently associated with allograft rejection and has not been clearly linked to increased mortality. Typical cavotricuspid isthmus-dependent flutter remains the most common post-transplant atrial tachyarrhythmia and is generally amenable to catheter ablation with high success rates. Other supraventricular tachyarrhythmias observed after OHT include atrial macro-reentrant tachycardia, recipient-to-donor atrial conduction tachycardia and atrioventricular or atrioventricular nodal re-entrant tachycardia.21

Decisions regarding anticoagulation in heart transplant recipients with AF are currently guided by principles extrapolated from the broader non-transplant population, as no transplant-specific recommendations exist. Standard thromboembolic risk stratification tools, such as CHA₂DS₂-VASc, are commonly applied; however, their validity in this population remains uncertain, particularly given the unique haemodynamic and graft-related factors that influence risk. Therefore, anticoagulation decisions should incorporate individualised assessment of bleeding risk, graft function and comorbidities. In addition, potential pharmacokinetic interactions between oral anticoagulants and calcineurin-based immunosuppressive regimens warrant heightened monitoring to ensure therapeutic safety and efficacy. Multidisciplinary collaboration is essential to optimise anticoagulation strategies in this vulnerable patient population.20

Special Considerations in Post-transplant AF

The management of AF in heart transplant recipients involves unique challenges due to the complex interplay between immunosuppressive therapy, graft physiology and arrhythmogenic substrates. Immunosuppression remains the cornerstone of post-transplant care to prevent acute and chronic graft rejection; however, certain immunosuppressive agents have been implicated in the pathogenesis of atrial arrhythmias, including AF.

Among these, purine synthesis inhibitors, such as azathioprine, have been linked to an increased incidence of atrial arrhythmias. Azathioprine’s immunomodulatory effects, while beneficial in reducing rejection, may contribute to alterations in atrial electrophysiology and promote proarrhythmic conditions through mechanisms that remain incompletely elucidated.20,22 Furthermore, emerging clinical evidence highlights a notable association between elevated serum trough levels of calcineurin inhibitors, particularly tacrolimus, and the development of atrial arrhythmias. Tacrolimus is a potent immunosuppressive agent widely used in heart transplant recipients; however, its narrow therapeutic window and variable pharmacokinetics pose challenges in maintaining optimal dosing.

Several studies, primarily in recipients of other solid organ transplants, such as kidney and liver, have documented that supratherapeutic tacrolimus levels correlate with an increased risk of atrial arrhythmias, including AF.23 Although data specific to the heart transplant population remain limited, this association is physiologically plausible given tacrolimus’s known effects on calcium handling and myocardial conduction pathways, which may predispose to electrical instability. The potential proarrhythmic effect of tacrolimus necessitates vigilant therapeutic drug monitoring and individualised dosing strategies to mitigate arrhythmia risk while preserving immunosuppressive efficacy.

Management of new-onset AF post-transplantation mandates a multidisciplinary approach that integrates expertise from transplant cardiology, electrophysiology, clinical pharmacology and transplant pharmacy. This collaborative framework is critical to balancing immunosuppression optimisation, arrhythmia control and prevention of adverse drug interactions. Individualised treatment plans should address rate versus rhythm control strategies, anticoagulation considerations given altered bleeding and thrombotic risk profiles, and close monitoring for rejection or infection, both of which can precipitate arrhythmias. Given the complexity of these patients, therapeutic decisions should be guided by a comprehensive evaluation of graft function, arrhythmia burden and overall clinical status.

Long-term Prognosis and Outcomes

AF occurring early in the postoperative course following heart transplantation is a common clinical observation, often attributed to perioperative factors, such as inflammation, surgical trauma and transient autonomic imbalance. However, the emergence of late-onset AF, defined as new episodes occurring beyond the immediate postoperative period, warrants heightened clinical vigilance, as it may signify underlying pathological processes.

Late AF in heart transplant recipients has been increasingly recognised as a marker of adverse prognosis, frequently correlating with complications, such as allograft rejection, cardiac allograft vasculopathy or progressive graft dysfunction. Several studies have demonstrated that late-onset AF is associated with increased morbidity and mortality, with some evidence suggesting a higher risk of graft failure and adverse cardiovascular events in this subgroup.24 The presence of AF in the late post-transplant period should therefore prompt comprehensive evaluation to identify reversible causes, including biopsy-proven rejection, ischaemia or structural changes within the graft.

Moreover, long-term outcomes in heart transplant recipients with AF may be influenced by the complex interplay of immunosuppression, arrhythmia-related haemodynamic compromise and thromboembolic risk. Optimising management strategies for AF in this population is critical not only to improve quality of life, but also to mitigate the risk of stroke and allograft deterioration.24

In summary, while AF is a frequent arrhythmia encountered in the early post-transplant period, late-onset AF should be considered a potentially ominous sign necessitating prompt diagnostic and therapeutic intervention. Continued research is needed to better elucidate the pathophysiological mechanisms linking AF with graft outcomes, and to develop tailored management protocols that improve long-term survival and graft function in heart transplant recipients.

Knowledge Gaps and Future Directions

Although considerable progress has been made in characterising AF after heart transplantation, several critical gaps persist. Current literature is limited by small, retrospective cohorts, and lacks multicentre prospective studies that could establish robust epidemiologic data and outcome associations. The absence of transplant-specific guidelines for AF management – particularly in regard to rhythm control strategies, use of anticoagulation and long-term arrhythmia surveillance – poses challenges in clinical decision-making.

Importantly, there is a need for larger prospective studies to evaluate the safety, efficacy and long-term outcomes of catheter ablation for AF in heart transplant recipients. Existing data are limited to case reports and small series, and further research is necessary to determine appropriate patient selection, procedural timing and outcomes in this unique population.

The development of transplant-specific risk prediction tools and consensus guidelines is imperative to improving long-term outcomes in this high-risk group.

Conclusion

AF following orthotopic heart transplantation presents a distinct clinical entity influenced by unique anatomical, physiological and pharmacological factors. While early postoperative AF is frequently transient, late-onset AF often signifies underlying graft pathology and portends worse outcomes. A comprehensive diagnostic workup – including ECG, echocardiography and invasive monitoring – is critical in identifying contributing factors, such as rejection, vasculopathy or structural remodelling.

Management strategies must be individualised, accounting for immunosuppressive drug interactions and the limitations of conventional arrhythmia therapies in the denervated heart. Given the lack of transplant-specific guidelines, a multidisciplinary approach involving transplant cardiology, electrophysiology and pharmacology is essential. Advancing our understanding of the epidemiology, pathophysiology and optimal treatment of AF in heart transplant recipients remains a priority to enhance graft longevity and patient survival.

Clinical Perspective

• AF may serve as an early marker of graft dysfunction, such as acute rejection or cardiac allograft vasculopathy, in heart transplant recipients. Its occurrence, especially late-onset AF, should prompt thorough diagnostic evaluation for reversible causes to prevent graft deterioration.

• Management of AF in the post-transplant population requires an individualised, multidisciplinary approach that considers the unique challenges of the denervated heart, potential drug interactions with immunosuppressants and limitations of conventional therapies, such as digoxin.

• Lack of transplant-specific guidelines highlights the need for improved surveillance and standardised management protocols for AF after heart transplantation. Clinical decision-making should integrate emerging evidence and prioritise rhythm monitoring, graft evaluation and personalised anticoagulation strategies.